Abstract:
Haemorrhagic septicaemia (HS), an economically important disease of cattle and
buffaloes, is caused by Pasteurella multocida B:2. Vaccination against this
disease is widely practiced but the protection was unclear. In order to improve
the protection effectiveness of the vaccines, the causative organism has been
fractionated and the various cell surface components were studied. The fimbrial
proteins are particularly attractive candidate for development of recombinant
vaccine because they are strong immunogens. This study was conducted to
characterize and determine the antigenicity of the fimbrial protein of Pasteurella
multocida B:2, followed by development of recombinant cell vaccine expressing
the fimbrial protein. The study also was carried out on the potential and efficacy
of Pasteurella multocida B:2 recombinant fimbrial proteins in the production of
vaccine against haemorrhagic septicaemia.
